Regulatory Regulatory decision

Acadia Pharmaceuticals' Trofinetide Rejected by EU Regulator

Analysis based on 10 articles · First reported Feb 02, 2026 · Last updated Mar 02, 2026

Sentiment

-20

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The negative opinion from the European Union===European Medicines Agency for trofinetide will likely lead to a decrease in Acadia Pharmaceuticals Inc.'s stock price due to the reduced market opportunity in the European Union. This decision could also impact investor confidence in Acadia Pharmaceuticals Inc.'s pipeline and regulatory success in other regions.

Pharmaceuticals Biotechnology

Event Summary

Acadia Pharmaceuticals Inc. announced that the European Union===European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion regarding the marketing authorization application for trofinetide, a treatment for Rett syndrome. The CHMP cited limited treatment effect, incomplete capture of core symptoms, and patient discontinuations affecting longer-term outcome assessment as reasons for refusal. Despite this, Acadia Pharmaceuticals Inc. intends to request a re-examination of the opinion, emphasizing the meaningful benefits observed in its LAVENDER trial and the drug's existing approvals in the United States, Canada, and Israel. Catherine Owen Adams, CEO of Acadia Pharmaceuticals Inc., expressed disappointment but reaffirmed commitment to bringing the therapy to patients in the European Union.

Key Actions

100 European Union===European Medicines Agency Adopted negative opinion on marketing authorization application Acadia Pharmaceuticals

80 Acadia Pharmaceuticals Intends to request re-examination of opinion European Union===European Medicines Agency

Entities Involved

stock

Acadia Pharmaceuticals

Acadia Pharmaceuticals Inc. received a negative opinion from the European Union===European Medicines Agency's Committee for Medicinal Products for Human Use regarding the marketing authorization for trofinetide. This decision impacts Acadia Pharmaceuticals Inc.'s ability to commercialize trofinetide in the European Union, potentially limiting its market reach and revenue from this drug.

Importance 100 Sentiment -50

govactor

European Union===European Medicines Agency

The European Union===European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on trofinetide, preventing its approval in the European Union for now. This decision reflects the agency's role in regulating pharmaceutical products within the European Union.

Importance 80 Sentiment 0

alliance

European Union

The European Union is the region where the European Union===European Medicines Agency's decision impacts the availability of trofinetide. The negative opinion means trofinetide will not be immediately available to patients in the European Union.

Importance 60 Sentiment 0

per

Catherine Owen Adams

Catherine Owen Adams, CEO of Acadia Pharmaceuticals Inc., expressed disappointment regarding the CHMP's recommendation but reiterated the company's commitment to bringing trofinetide to patients and working with EU regulators.

Importance 30 Sentiment 0

per

Schulze method

Schulze method, a caregiver and member of the Rett Syndrome Society Nordrhein-Westfalen, expressed hope for trofinetide's approval in the EU, highlighting the patient community's perspective.

Importance 10 Sentiment 0

cnt

United States

Trofinetide is already approved in the United States, indicating a different regulatory outcome compared to the European Union.

Importance 10 Sentiment 0

cnt

Canada

Trofinetide is already approved in Canada, indicating a different regulatory outcome compared to the European Union.

Importance 10 Sentiment 0

+ 1 more entities View on Dashboard

Relationships

Acadia Pharmaceuticals related ↔ European Union===European Medicines Agency